Loading
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$7.35
−$0.28 · -3.67%
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Previous close
$7.35
−$0.28 · -3.67%
Regular session · ET · Market data may be delayed.
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Day range
Current $7.35
52-week range
Current $7.35
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
43
Mixed
Risk
76
High Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Day range
Current $7.35
52-week range
Current $7.35
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cost of goods sold | 404.54K USD | 392.74K USD | 745.59K USD | 769.69K USD | 604.4K USD |
| Gross profit | −404.54K USD | −392.74K USD | −745.59K USD | −769.69K USD | −604.4K USD |
| Research and development | 1.3M USD | 948.29K USD | 1.07M USD | 1.58M USD | 2.51M USD |
| Selling, general, and administrative | 10.02M USD | 2.43M USD | 2.92M USD | 4.69M USD | 5.11M USD |
| Operating expenses | 11.32M USD | 3.38M USD | 3.99M USD | 6.27M USD | 7.62M USD |
| Depreciation and amortization | 404.54K USD | 392.74K USD | 745.59K USD | 769.69K USD | 604.4K USD |
| Operating income | −11.72M USD | −3.77M USD | −4.74M USD | −6.27M USD | −7.62M USD |
| Net income | −11.7M USD | −3.58M USD | −4.3M USD | −5.87M USD | −7.42M USD |
Company facts updated Oct 10, 2026.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
